DENVER, Colo., Oct 16, 2023 (www.247marketnews.com)- Ambrx Biopharma, Inc. (NASDAQ: AMAM) stated, this morning, that it published two abstracts detailing updated safety and efficacy data from the ongoing Phase 1/2 trial, APEX-01 (NCT04662580), evaluating ARX517 for metastatic castration-resistant prostate cancer (mCRPC) and were made available as part of the 2023 European Society of Medical Oncology (ESMO) Congress 2023 meeting, taking place in Madrid, Spain, October 20-24, 2023.
Key updates from the newly published abstract include:
- ≥50% PSA reduction observed across putative therapeutic dose levels ≥2.0 mg/kg – 3 of 3 in Cohort 6 (2.0 mg/kg), 2 of 3 in Cohort 7 (2.4 mg/kg) and 2 of 3 in Cohort 8 (2.88 mg/kg)
- No drug-related severe adverse events (SAEs) and no dose limiting toxicities (DLTs) observed in any cohort
- Pharmacokinetic (PK) data indicated strong ADC stability preventing premature release of anticancer payload
Ambrx Biopharma is trading at $16.63, up $2.58 (+18.36%), on 473.1K premarket shares traded.
Its 52-week range is $0.38 to $16.86. It’s near a 52-week high and hit a premarket high of $20.67, so this could be a big mover today.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.